David Cristina

Dr. David Cristina is an experienced life sciences and healthcare investor investing across life sciences, digital health and healthcare services. David led Fosun’s healthcare investment team in Europe and was seconded to Arix Biosciences investment team as a Principal, where he actively sourced and ran due diligence on life sciences investment opportunities. Prior to joining Fosun, David was at Portugal Ventures, where he helped set up the life sciences investment team. David has served on the boards of Lymphact (acquired by Gamma Delta Technologies), Immunethep and Tonic App. Prior to this, David founded Acelera Therapeutics a venture backed cell therapy company based on R&D from Dr. Luís Graça’s lab at the Instituto de Medicina Molecular in Lisbon.

David created Triple Helix Technologies, a consulting company running the technology transfer activities of Instituto Gulbenkian de Ciência, CEDOC and Institute for the Unknown (Champalimaud). David also spent time in the Portuguese Government developing programs to improve economic impacts of R&D investments.  He trained as a PhD in Genetics of Aging under Cynthia Kenyon at University of California San Francisco (UCSF).